If the risk of mass delistings is as real as some claim, with the obvious implications for patients, then surely it needs to be part of any forum hosted by or even involving the industry?
Surely the best 'patient view' is one that is fully informed?
September 2, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Medicines Australia backs focus on listings and productivity in government brief
July 3, 2025 - - Latest News -
AusBiotech seeking a head of investment to drive sector growth
July 3, 2025 - - Australian Biotech -
What's the point of pretending that Australia doesn't free-ride on US innovation?
July 3, 2025 - - Latest News -
Framework pushes genomics funding to a review that is mostly silent on it
July 3, 2025 - - Latest News -
Draft 'National Health Genomics Policy Framework' out for consultation
July 3, 2025 - - Latest News -
MedAdvisor announces agreement confirming the sale of Australian business
July 3, 2025 - - Latest News -
GBMA announces planned departure of long-standing CEO
July 2, 2025 - - Latest News